Skip to main content

Table 7 Univariate and multivariate Cox regression analysis for prognostic value of study variables to predict RFS in HER2-amplified breast cancer

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Characteristic

Univariate analysis Multivariate analysis

n 

p

Mean RFS

95% CI for RFS

p

Exp (B)

95% CI for Exp (B)

Estrogen receptor status

177

0.090

     

Progesterone receptor status

177

0.176

     

Histological grade

174

0.831

     

Ki-67 proliferation index

177

0.171

     

Histological type (lobular/ductal)

168

0.774

     

Lymph nodal status pN+ (vs pN0)

169

0.000***

6.7 (8.4)

5.9 (8.0) – 7.5 (8.7)

0.002**

3.486

1.608, 7.555

Tumor size TNM stage ≥ pT3 (vs < pT3)

172

0.000***

4.2 (7.9)

2.3 (7.5) – 6.2 (8.3)

0.001***

4.016

1.703, 9.468

Patient age at diagnosis

177

0.118

     

Menopausal status

176

0.082

     

Cytokeratin 5/14 expression

167

0.447

     

Basal phenotype (CK5/14+, ER-)

167

0.955

     

Total cellular HER3 low (vs high)

177

0.004**

6.3 (8.0)

5.3 (7.6) – 7.3 (8.4)

0.020*

2.305

1.143, 4.648

Membranous HER3 low (vs high)

177

0.025*

6.6 (7.9)

5.6 (7.4) – 7.7 (8.3)

   

Cytoplasmic HER3 low (vs high)

177

0.010*

5.9 (7.8)

4.2 (7.4) – 7.6 (8.2)

   

NEDD4–1 expression

145

0.261

     

NRDP1 nuclear expression

145

0.689

     

NRDP1 cytoplasmic expression

145

0.711

     
  1. Significant p-value (marked as *p<0.05, **p≤0.01, ***p≤0.001) means prognostic value of the variable to predict shorter RFS-time. Mean follow-up period for HER2+ BCA cohort was 5.3 years. Estimated mean RFS time is announced in years for each significant character